Experimental vaccine for Ebola indicates it's safe and effective
There were a few common side effects to the drug: pain at the injection site and a transient fever that dissolved between 12 and 36 hours after the subjects received their injections.
VSV-ZEBOV is just one of two experimental Ebola vaccines being tested in a Phase 2/3 PREVAIL clinical trial in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” National Institute of Allergy and Infectious Diseases Director Anthony Fauci said. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
The study, sponsored by the U.S. government and conducted at the National Institutes of Health and the Walter Reed Army Institute of Research, has been published online in The New England Journal of Medicine.